Profile data is unavailable for this security.
About the company
Kaken Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the pharmaceutical and real estate businesses. The Company has two business segments. The Pharmaceutical Business segment is primarily engaged in the manufacture and sale of pharmaceuticals, medical equipment, and agricultural chemicals. The Real Estate Business segment is primarily engaged in the rental of real estate related to Bunkyo Green Court.
- Revenue in JPY (TTM)75.66bn
- Net income in JPY-3.83bn
- Incorporated1948
- Employees1.13k
- LocationKaken Pharmaceutical Co Ltd20F, Bunkyo Green Court Center Office2-28-8, HonkomagomeBUNKYO-KU 113-8650JapanJPN
- Phone+81 359775001
- Fax+81 359775131
- Websitehttps://www.kaken.co.jp
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kyorin Pharmaceutical Co Ltd | 133.26bn | 10.77bn | 99.87bn | 2.00k | 8.89 | 0.6892 | 6.49 | 0.7495 | 187.40 | 187.40 | 2,319.59 | 2,417.37 | 0.6927 | 1.08 | 2.93 | 66,695,200.00 | 5.60 | 3.34 | 7.03 | 4.16 | 45.32 | 45.89 | 8.08 | 5.11 | 2.05 | -- | 0.1746 | 57.34 | 8.83 | 3.41 | 70.73 | 8.12 | 14.36 | -7.06 |
| Katakura Industries Co Ltd | 40.98bn | 5.84bn | 106.53bn | 941.00 | 16.59 | 1.06 | 12.11 | 2.60 | 182.30 | 182.30 | 1,278.51 | 2,853.06 | 0.2926 | 2.15 | 6.42 | 43,545,160.00 | 4.27 | 2.60 | 5.20 | 3.57 | 36.16 | 37.98 | 14.59 | 9.44 | 2.63 | -- | 0.0807 | 23.42 | -1.37 | -2.19 | 15.73 | 15.27 | -7.22 | 33.03 |
| Zeria Pharmaceutical Co Ltd | 86.61bn | 7.26bn | 113.33bn | 1.75k | 13.45 | 1.02 | 7.79 | 1.31 | 164.79 | 164.79 | 1,964.97 | 2,178.21 | 0.5366 | 1.27 | 3.21 | 49,607,640.00 | 4.49 | 4.67 | 6.99 | 7.47 | 72.76 | 72.17 | 8.37 | 9.02 | 0.9739 | 11.41 | 0.2984 | 28.75 | 15.30 | 7.64 | 28.52 | 27.71 | 16.51 | 6.69 |
| Mochida Pharmaceutical Co Ltd | 111.92bn | 6.42bn | 135.73bn | 1.51k | 20.59 | 0.9621 | 14.46 | 1.21 | 181.16 | 181.16 | 3,156.95 | 3,876.77 | 0.6427 | 1.67 | 3.02 | 74,214,190.00 | 3.69 | 4.50 | 4.47 | 5.44 | 48.43 | 52.49 | 5.74 | 6.87 | 2.85 | -- | 0.0678 | 43.01 | 2.21 | 0.6516 | 25.03 | 4.34 | 1.98 | 0.00 |
| Kaken Pharmaceutical Co Ltd | 75.66bn | -3.83bn | 186.49bn | 1.13k | -- | 1.10 | -- | 2.46 | -97.11 | -97.11 | 1,980.56 | 3,850.39 | 0.4091 | 1.86 | 2.80 | 67,195,380.00 | -2.07 | 5.99 | -2.42 | 6.87 | 53.09 | 56.17 | -5.06 | 12.91 | 3.21 | -- | 0.0257 | 59.58 | 30.52 | 1.05 | 73.77 | -6.36 | 14.81 | 0.00 |
| Towa Pharmaceutical Co Ltd | 269.92bn | 21.44bn | 191.64bn | 4.79k | 8.54 | 0.9654 | 4.40 | 0.71 | 435.61 | 435.61 | 5,483.17 | 3,853.29 | 0.5695 | 1.49 | 3.37 | 56,374,690.00 | 4.52 | 3.89 | 5.53 | 5.07 | 36.72 | 37.81 | 7.94 | 6.61 | 1.54 | 32.77 | 0.5519 | 21.52 | 13.89 | 18.65 | 17.39 | 5.53 | 46.23 | 9.73 |
| Kissei Pharmaceutical Co Ltd | 95.29bn | 14.14bn | 216.42bn | 1.78k | 13.78 | 0.8908 | 11.46 | 2.27 | 337.47 | 337.47 | 2,274.29 | 5,220.29 | 0.3748 | 1.85 | 2.83 | 53,596,180.00 | 5.62 | 4.26 | 6.19 | 4.60 | 48.21 | 48.59 | 14.99 | 14.30 | 3.42 | -- | 0.0058 | 32.41 | 16.87 | 6.91 | 7.18 | 33.54 | 31.04 | 13.97 |
| Sawai Group Holdings Co Ltd | 200.68bn | -1.25bn | 264.52bn | 3.31k | -- | 1.48 | 18.31 | 1.32 | -9.86 | -22.64 | 1,734.07 | 1,548.25 | 0.5445 | 1.28 | 3.40 | 60,628,400.00 | -0.3389 | -0.2327 | -0.4542 | -0.3187 | 28.89 | 32.95 | -0.6224 | -0.475 | 1.08 | -1.04 | 0.4066 | 191.65 | 6.88 | 0.7009 | -87.38 | -35.38 | 8.65 | 4.11 |
Data as of Feb 13 2026. Currency figures normalised to Kaken Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
11.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 1.17m | 2.64% |
| Nomura Asset Management Co., Ltd.as of 08 Jan 2026 | 936.20k | 2.12% |
| Brandes Investment Partners LPas of 04 Feb 2026 | 539.20k | 1.22% |
| Amova Asset Management Co., Ltd.as of 09 Jan 2026 | 432.50k | 0.98% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 431.90k | 0.98% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2025 | 416.80k | 0.94% |
| Asset Management One Co., Ltd.as of 08 Jan 2026 | 362.00k | 0.82% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 08 Jan 2026 | 359.50k | 0.81% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 337.41k | 0.76% |
| TIAA-CREF Investment Management LLCas of 31 Dec 2025 | 302.78k | 0.69% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
